Study 15 of 108 for search of: Spasticity
Previous Study Return to Search Results Next Study

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Effects on Quality of Life Following Dysport Treatment in Post-Stroke Spasticity of the Arm
This study has been completed.
Sponsored by: Ipsen
Information provided by: Ipsen
ClinicalTrials.gov Identifier: NCT00216411
  Purpose

The main purpose of this study is to assess the effect on Quality of Life of two cycles of Dysport treatment on post-stroke spasticity of the upper limb. The effect of treatment on spasticity and function will also be measured.


Condition Intervention Phase
Cerebrovascular Accident
Muscle Spasticity
Drug: Botulinum type A toxin (Dysport)
Phase IV

MedlinePlus related topics: Botox
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Official Title: A Prospective Phase IV, Multicentre, Placebo-Controlled Study to Demonstrate Changes in the Quality of Life Following DYSPORT Intramuscular Injection in the Treatment of Upper Limb Spasticity in Adult Post-Stroke Patients

Further study details as provided by Ipsen:

Primary Outcome Measures:
  • Change in quality of life measured using the Assessment of Quality of Life questionnaire (12 question version).

Secondary Outcome Measures:
  • Change in muscle spasticity assessed on Modified Ashworth Scale (MAS)
  • Change in the Modified Motor Assessment Scale
  • Change in patient disability and carer burden rating scale total score
  • Achievement of the patient identified functional outcome measures (Goal Attainment Scaling)
  • Change in the degree of pain
  • Change in depression rating scale total score
  • Global assessment of benefit

Estimated Enrollment: 102
Study Start Date: November 2004
Estimated Study Completion Date: October 2006
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • The patient has suffered a stroke, as defined by the World Health Organisation (WHO) criteria, at least 6 months previously.
  • The patient has a hemiparetic arm and meets minimum score requirements on the Modified Ashworth Scale.
  • The patient has the cognitive and communication ability to participate in the study.

Exclusion Criteria:

  • Patients who have received botulinum toxin treatment within the past 120 days.
  • Contraindication to botulinum toxin treatment.
  • Patients who are receiving oral anti-spasticity medication and who have had a change in dosage of this medication in the month prior to study entry.
  • Patients who have previously been treated with phenol for their upper limb spasticity.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00216411

Locations
Australia, New South Wales
St Josephs Hospital
Auburn, New South Wales, Australia, 2144
Prince of Wales Hospital
Randwick, New South Wales, Australia, 2031
Royal Prince Alfred Hospital
Camperdown, New South Wales, Australia, 2050
Australia, Victoria
Box Hill Hospital
Box Hill, Victoria, Australia, 3128
Caulfield General Medical Centre
Caulfield, Victoria, Australia, 3162
Austin Health
Heidelberg, Victoria, Australia, 3084
Sponsors and Collaborators
Ipsen
Investigators
Study Director: Hugues Berard, MD Ipsen
  More Information

Study ID Numbers: A-9B-52120-097
Study First Received: September 13, 2005
Last Updated: October 11, 2007
ClinicalTrials.gov Identifier: NCT00216411  
Health Authority: Australia: Department of Health and Ageing Therapeutic Goods Administration

Study placed in the following topic categories:
Cerebral Infarction
Stroke
Vascular Diseases
Quality of Life
Central Nervous System Diseases
Ischemia
Brain Diseases
Cerebrovascular Disorders
Signs and Symptoms
Muscle Spasticity
Botulinum Toxins
Muscular Diseases
Musculoskeletal Diseases
Muscle Hypertonia
Neurologic Manifestations
Brain Ischemia
Brain Infarction
Botulinum Toxin Type A
Infarction

Additional relevant MeSH terms:
Neuromuscular Manifestations
Physiological Effects of Drugs
Nervous System Diseases
Neuromuscular Agents
Cardiovascular Diseases
Peripheral Nervous System Agents
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 30, 2009